Drug Profile
Babim
Latest Information Update: 10 Dec 1998
Price :
$50
*
At a glance
- Originator University of North Carolina
- Developer Celera Genomics Group; University of North Carolina
- Class Antirheumatics; Antivirals
- Mechanism of Action Trypsin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatic disorders; Viral infections
Most Recent Events
- 10 Dec 1998 Discontinued-Preclinical for Rheumatic disorders in USA (Unknown route)
- 10 Dec 1998 Discontinued-Preclinical for Viral infections in USA (Unknown route)
- 06 Apr 1998 New profile